A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.
Epistemonikos ID: 8807319ce2a85e0dd82ad35f2dfad973ebb212ba
First added on: May 15, 2024